[Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis]
- PMID: 7663658
- DOI: 10.1016/0929-693x(96)81224-3
[Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis]
Abstract
Mucociliary transport is a major component of respiratory function and contributes greatly to the protection of the airways against infection. Cystic fibrosis is associated with severe abnormalities of the capacities of transport, due to the abnormal mucus and inflammatory changes of the epithelium. Recombinant human DNase I (rhDNase) has been demonstrated to reduce the viscosity of purulent cystic fibrosis respiratory mucus. To investigate the impact of rhDNase on transport capacities, we analysed ex vivo its effect on mucus transport by the ciliary activity and by the simulated cough. We measured in parallel the changes in rheological and physical properties of mucus. In 15 patients with cystic fibrosis, rhDNase was able in vitro to improve mucus transport capacities by simulated cough. The effect was dose-dependent and correlated with a decrease in viscosity and an improvement of surface properties of the mucus. A significant improvement of mucociliary transport was observed only in the subgroup of patients whose transport capacities were altered before incubation with rhDNase. Our findings suggest that rhDNase in vivo might benefit most to patients whose mucus transport capacities are altered, because of highly viscous and tenacious secretions.
Similar articles
-
Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.Eur Respir J. 1995 Mar;8(3):381-6. doi: 10.1183/09031936.95.08030381. Eur Respir J. 1995. PMID: 7789481
-
Effects of rhDNase on purulent airway secretions in chronic bronchitis.Eur Respir J. 1996 Apr;9(4):765-9. doi: 10.1183/09031936.96.09040769. Eur Respir J. 1996. PMID: 8726943
-
Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.Am J Respir Crit Care Med. 1997 Jul;156(1):173-7. doi: 10.1164/ajrccm.156.1.9512074. Am J Respir Crit Care Med. 1997. PMID: 9230743 Clinical Trial.
-
Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches.Respiration. 1995;62 Suppl 1:2-12. doi: 10.1159/000196486. Respiration. 1995. PMID: 7792436 Review.
-
Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.Chest. 1995 Feb;107(2 Suppl):65S-70S. doi: 10.1378/chest.107.2_supplement.65s. Chest. 1995. PMID: 7842816 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical